Latest Period
Q2 2026
CUSIP: 46124U107
Latest Period
Q2 2026
Institutions Reporting
88
Shares (Excl. Options)
84,640,508
Price
$3.78
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 88 institutions filings for Q2 2026.
Security key
46124U107
Latest holder period
Q2 2026
13F holders
88
13D/G owners
10
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 46124U107:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sofinnova Crossover I | 8.6% | +20% | $108,981,346 | +$64,487,273 | 19,086,050 | +145% | Sofinnova Partners SAS, a French corporation | 31 Dec 2025 |
| Invus Global Management, LLC | 11% | +35% | $49,037,031 | +$24,518,517 | 14,814,813 | +100% | Invus Public Equities, L.P. | 30 Jun 2025 |
| Andera Partners | 7.7% | -12% | $80,593,658 | +$10,381,814 | 14,114,476 | +15% | Andera Partners | 31 Dec 2025 |
| Samsara BioCapital, L.P. | 7.4% | +25% | $56,191,805 | +$22,319,746 | 13,540,194 | +66% | Srinivas Akkaraju | 17 Nov 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 5% | -18% | $39,714,931 | +$4,251,111 | 9,569,863 | +12% | BVF PARTNERS L P/IL | 17 Nov 2025 |
| New Enterprise Associates 17, L.P. | 4.9% | -18% | $57,827,646 | +$6,303,642 | 9,372,390 | +12% | New Enterprise Associates 17, L.P. | 30 Mar 2026 |
| Deep Track Capital, LP | 3.8% | -38% | $42,902,558 | -$21,276,849 | 7,800,465 | -33% | Deep Track Capital, LP | 31 Mar 2026 |
| Yiheng Capital Management, L.P. | 5.5% | -36% | $43,962,416 | +$18,899,084 | 7,597,148 | +75% | Yiheng Capital Partners, L.P. | 30 Sep 2025 |
| PERCEPTIVE ADVISORS LLC | 5% | -14% | $42,246,764 | +$10,098,434 | 7,300,666 | +31% | Perceptive Advisors LLC | 30 Sep 2025 |
| Broqua Pierre | 4.3% | $15,365,625 | 4,097,500 | Pierre Broqua | 31 Dec 2024 |
As of 30 Jun 2026, 88 institutional investors reported holding 84,640,508 shares of Inventiva S.A. - Ordinary shares, nominal value 0.01 EUR per share (IVA). This represents 41% of the company’s total 207,459,176 outstanding shares.
13F concentration
Largest 13F positions for this security by reported shares and value.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Caligan Partners LP | 3.9% | 8,163,191 | +64% | 1.5% | $30,856,862 |
| SAMSARA BIOCAPITAL, LLC | 3% | 6,314,805 | +22% | 2% | $23,869,963 |
| Paradigm Biocapital Advisors LP | 1.9% | 4,000,000 | 0% | 0.28% | $15,120,000 |
| ANDERA PARTNERS | 1.8% | 3,633,181 | +100% | 6.7% | $13,733,424 |
| ADAR1 Capital Management, LLC | 1.7% | 3,606,656 | +66% | 0.65% | $13,633,160 |
| MILLENNIUM MANAGEMENT LLC | 1.7% | 3,512,174 | +18% | 0.01% | $13,276,018 |
| Nantahala Capital Management, LLC | 1.3% | 2,686,393 | 0.61% | $10,154,566 | |
| Trails Edge Capital Partners, LP | 1.3% | 2,657,997 | 0% | 1.6% | $10,047,228 |
| FRANKLIN RESOURCES INC | 1.3% | 2,642,611 | +7.4% | 0% | $9,989,070 |
| Squadron Capital Management LLC | 1.2% | 2,435,000 | +355% | 3.2% | $9,204,300 |
| Woodline Partners LP | 1.1% | 2,323,149 | 0.03% | $8,781,503 | |
| Aberdeen Group plc | 1.1% | 2,307,773 | 0.01% | $8,723,382 | |
| UBS Group AG | 1.1% | 2,305,192 | -0.58% | 0% | $8,713,626 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.97% | 2,003,782 | +36% | 0.15% | $7,574,296 |
| Patient Square Capital LP | 0.95% | 1,967,171 | 1.2% | $7,435,906 | |
| NEXTBio Capital Management LP | 0.86% | 1,787,984 | +34% | 3.1% | $6,758,580 |
| CITADEL ADVISORS LLC | 0.86% | 1,784,566 | +2648% | 0% | $6,745,659 |
| AMERIPRISE FINANCIAL INC | 0.82% | 1,697,148 | +101% | 0% | $6,415,219 |
| Point72 Asset Management, L.P. | 0.81% | 1,683,012 | +76% | 0.01% | $6,361,785 |
| Integral Health Asset Management, LLC | 0.73% | 1,520,000 | +280% | 0.24% | $5,745,600 |
| Yu Fan | 0.72% | 1,500,000 | 0% | 5.3% | $5,670,000 |
| NEA Management Company, LLC | 0.7% | 1,462,586 | 0% | 0.35% | $5,528,575 |
| STEMPOINT CAPITAL LP | 0.69% | 1,426,320 | 0.93% | $5,391,490 | |
| JPMORGAN CHASE & CO | 0.63% | 1,309,100 | 0% | $4,647,305 | |
| Propel Bio Management, LLC | 0.62% | 1,281,212 | +77% | 2.5% | $4,842,981 |
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 84,640,508 | $319,469,971 | +$127,767,919 | $3.78 | 88 |
| 2026 Q1 | 52,362,514 | $290,384,522 | +$33,010,984 | $5.55 | 65 |
| 2025 Q4 | 46,711,433 | $217,189,873 | +$153,107,827 | $4.65 | 53 |
| 2025 Q3 | 5,106,787 | $29,415,940 | +$1,094,859 | $5.79 | 15 |
| 2025 Q2 | 4,928,159 | $15,667,628 | +$214,859 | $3.19 | 12 |
| 2025 Q1 | 4,860,363 | $12,214,319 | -$1,721,340 | $2.94 | 8 |
| 2024 Q4 | 5,447,098 | $11,663,912 | +$1,275,982 | $2.14 | 7 |
| 2024 Q3 | 4,851,351 | $9,059,439 | -$1,414 | $1.86 | 7 |
| 2024 Q2 | 4,845,553 | $14,461,203 | -$19,438 | $2.99 | 7 |
| 2024 Q1 | 4,849,836 | $17,555,978 | -$52,773 | $3.62 | 8 |
| 2023 Q4 | 4,860,874 | $21,917,529 | +$26,077 | $4.52 | 8 |
| 2023 Q3 | 4,855,354 | $20,589,732 | +$102,187 | $4.20 | 7 |
| 2023 Q2 | 4,830,074 | $19,513,567 | -$1,019,078 | $4.04 | 8 |
| 2023 Q1 | 5,129,875 | $18,275,932 | +$1,089,878 | $3.64 | 8 |
| 2022 Q4 | 4,812,252 | $21,919,774 | -$19,722,477 | $4.44 | 6 |
| 2022 Q3 | 8,933,248 | $33,067,000 | -$1,003,809 | $3.86 | 7 |
| 2022 Q2 | 9,109,429 | $51,761,000 | +$29,343,302 | $5.77 | 10 |
| 2022 Q1 | 3,934,328 | $45,020,000 | +$2,060,118 | $11.40 | 9 |
| 2021 Q4 | 3,755,787 | $51,299,000 | +$608,002 | $13.66 | 10 |
| 2021 Q3 | 3,708,525 | $52,500,000 | +$30,368,738 | $14.16 | 11 |
| 2021 Q2 | 1,564,469 | $21,328,000 | -$848,745 | $13.58 | 14 |
| 2021 Q1 | 1,623,116 | $23,833,940 | -$15,643,566 | $14.69 | 13 |
| 2020 Q4 | 2,733,996 | $39,206,000 | -$22,116,536 | $14.50 | 15 |
| 2020 Q3 | 4,021,314 | $47,498,000 | +$47,498,000 | $11.81 | 17 |